LEX Diagnostics
Anieza Gkiokai is an experienced scientist specializing in reagent development and molecular diagnostics. Currently serving as a Reagent Development Scientist at LEX Diagnostics since May 2022, Anieza focuses on creating high-quality RT-PCR reagent systems for point-of-care applications. Previously, Anieza worked at Oncologica UK as a Senior Trainer and Genetic Technologist, where expertise in RNA extraction and NGS methodology was developed. An education background includes a Master of Science in Drug Delivery from Aston University, awarded with Distinction, and a B.Sc/M.Sc Integrated Master's degree in Biology from the University of Ioannina. Relevant research experience includes investigating the role of Scaffold Attachment Factor A in DNA expression at the Institute of Molecular Biology and Biotechnology. Additional skills encompass freelance interpretation and administrative roles.
LEX Diagnostics
LEX Diagnostics is a medical device company that specializes in molecular diagnostics for primary care. Having solved the PCR cost problem, LEX focuses tightly on nasal and oral samples, and on viral pathogens, to avoid the other high-cost elements of traditional molecular diagnostic products. LEX Diagnostics is a spin-out from TTP plc, atechnology development company in the life science and medical device sector. The origins of the LEX technology lie in an internal R&D project to reduce the time it takes to get a result from a PCR test. It formed a company when it became clear the solution also reduced the cost and size of any diagnostic device using it.LEX Diagnostics was founded in 2020 and is based in Melbourn, United Kingdom.